mAbxience | About us


mAbxience is a biotechnology company specialized in the research, development and manufacture of biosimilar monoclonal antibodies, part to the pharmaceutical Insud Pharma Group. Set up in 2009, it currently has two facilities for development and production, in Spain and Argentina. In December 2014, it launched its first biosimilar, rituximab, which is now approved and distributed in many markets globally. Its second product, bevacizumab, was launched in its first market in November 2016.

mAbxience maintains a deep commitment to quality and safety. With a passion for patient care, access and affordability of biologics the mAbxience team is working to bring its biosimilars to all countries around the world. Its working methodology is “fingerprint-like, biosimilars by design”, such that each product is highly similar to the original with the same genetic fidelity and precision as a human fingerprint.

Insud Pharma, founded in 1977, makes an enormous contribution to public health around the world through the medicines, and active pharmaceutical ingredients that it develops and manufactures. With over 6000 employees based in over 40 countries, Insud Pharma is a significant and respected enterprise in the pharmaceutical and healthcare sector.

mAbxience is a fully integrated biopharmaceutical company specialized in research, development and manufacturing of biosimilars for the treatment and/or prevention of several diseases in diverse therapeutic areas.